Search research articles
Contact Us
Filters
Showing results (211-220 of 213) with videos related to
Page
of 22
Sort By:
You have reached the last page of results.
This site can display upto 213 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 14, 2019
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
A T Shaw, G J Riely, Y-J Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2005
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle
A L Hamilton, J P Eder, A C Pavlick, et al.
British Journal of Cancer
|
June 25, 2014
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
A F Hezel, M S Noel, J N Allen, et al.
Page
of 22
Search research articles
Search
Showing results (211-220 of 213) with videos related to
Sort By:
Page
of 22
You have reached the last page of results.
This site can display upto 213 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 14, 2019
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
A T Shaw, G J Riely, Y-J Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2005
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle
A L Hamilton, J P Eder, A C Pavlick, et al.
British Journal of Cancer
|
June 25, 2014
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
A F Hezel, M S Noel, J N Allen, et al.
Page
of 22